A PILOT TRIAL OF TANDEM AUTOLOGOUS PERIPHERAL BLOOD PROGENITOR CELL TRANSPLANTATION FOLLOWING HIGH-DOSE THIOTEPA AND CARBOPLATIN IN CHILDREN WITH POOR-RISK CENTRAL NERVOUS SYSTEM TUMORS

REFERENCES

• Matthay K K, Reynolds C P, Villablanca J G, et al, 13-cis-Retinoic acid after intensive consolidation therapy for neuroblastoma improves event-free survival: a randomized Children's Cancer Group Study. New Engl J Med.. 1999; 341: 1097
   PubMed Web of Science ®Google Scholar
• Philips G L, Reece D L. Clinical studies of autologous bone marrow transplantation in Hodgkin's disease. Clin Haem at ol.. 1986; 15: 151–166
   PubMed Web of Science ®Google Scholar
• Jagannath S, Armitage J O, Dicke K A, et al, Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol.. 1989; 7: 179–185. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Carella A M, Congiu A M, Gaozza E, et al, High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin's disease patients: an Italian Group Report. J Clin Oncol.. 1988; 6: 1411–1416. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Wheeler C, Antin J H, Churchill W H, et al, Cyclophosphamide, carmustine and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose finding study. J Clin Oncol.. 1990; 8: 648–656. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Bureo E, Ortega J J, Munoz A, et al, Bone marrow transplantation in 46 pediatric patients with non-Hodgkin's lymphoma. Spanish Working Party for Bone Marrow Transplantation in Children. Bone Marrow Transplant. 1995; 15: 353, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Dunkel I J, Boyett J M, Yates A, et al, High-dose carboplatin, thiotepa and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma. Children's Cancer Group Study. J Clin Oncol.. 1998; 16: 222–228. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Finlay J, August C, et al, High dose multi-agent chemotherapy followed by bone marrow ‘rescue’ for malignant astrocytomas of childhood and adolescence. J Neuro-Oncol.. 1990; 9: 239–248
   PubMed Web of Science ®Google Scholar
• Guruangan S, Dunkel I J, Goldman S, et al, Myeloablative chemotherapy with autologous bone marrow rescue in young children with recurrent malignant brain tumors. J Clin Oncol.. 1998; 16: 2486–2493. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Garaventa A, Hartmann O, Bernard J L, et al, Autologous bone marrow transplantation for pediatric Wilms tumor: the experience of the European Bone Marrow Transplantation Solid Tumor Registry. Med Pediatr Oncol.. 1994; 22: 11–14. [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Kremens B, Gruhn B, Klingebiel T, et al, High-dose chemotherapy with autologous stem cell rescue in children with nephroblastoma. Bone Marrow Transplan. 2002; 30: 893–898
   PubMed Web of Science ®Google Scholar
• Philip T, Ladenstein R, Zucker J M, et al, Double megatherapy and autologous bone marrow transplantation for advanced neuroblastoma: the LMCE2 Study. Br J Cancer. 1993; 67: 119–127. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Grupp S A, Stem J W, Bunin N, et al, Tandem high dose therapy in rapid sequence for children with high-risk neuroblastoma. J Clin Oncol.. 2000; 18: 2567–2575. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Ahmed T, Lake D E, Beer M, et al, Single and double autotransplants for relapsing/refractory Hodgkin's disease: results of two consecutive trials. Bone Marrow Transplant. 1997; 19: 449–454. [CROSSREF], [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Bateman J C. Chemotherapy for solid tumors with trimethylene thiophosphoramide. N Engl J Med.. 1963; 242: 879–887
   Google Scholar
• Clamon G H. Alkylating agents, In. Perry Mc. The Chemotherapy Source Book. Baltimore, MD, Williams & Wilkins. 1992; 286–300
   Google Scholar
• Allen J C, Walker R, Luks E, et al, Carboplatin and recurrent childhood brain tumors. J Clin Oncol.. 1987; 5: 459–463. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Friedman H S, Krischer J P, Burger P, et al, Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin: a Pediatric Oncology Group randomized phase II study. J Clin Oncol.. 1992; 10: 249–256. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Kung F H, Desai S J, Dickerman J D, et al, Ifosfamide/carboplatin/etoposide (ICE) for recurrent malignant solid tumors of childhood: a Pediatric Oncology Group Phase I/II Study. J Pediatr Hematol Oncol.. 1995; 17: 265–269. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Abu-Ghosh A M, Krailo M D, Goldman S C, et al, Ifosfamide, carboplatin, and etoposide in children with poor-risk relapsed Wilms’ tumor: a Childrens Cancer Group report. Ann Oncol.. 2002; 13: 460–463. [CROSSREF], [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Teicher B A, Frei E III. Alkylating agents, In:. Gupta R S. Drug Resistance in Mammalian Cells. Vol 2, Boca Raton, FL, CRC. 1989
   Google Scholar
• De Vita V. Dose response is alive and well. J Clin Oncol.. 1986; 4: 1157–1158
   PubMed Web of Science ®Google Scholar
• Frei E, III, Cucchi C A, Rosowsky A, et al, Alkylating agent resistance: In vitro studies with human cell lines. Proc Natl Acad Sci USA. 1985; 82: 2158–2162. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Teicher B A, Cucchi C A, Lee J B, et al, Alkylating agents: in vitro studies of cross-resistance patterns in human cell lines. Cancer Res.. 1986; 46: 4379–4383. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Peters W P, Stuart A, Klotman M, et al, High-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support. Cancer Chemother Pharmacol.. 1989; 23: 377–383. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Williams S F, Bitran J D, Kaminer L, et al, A phase I-II study of bialkylator chemotherapy, high-dose thiotepa, and cyclophosphamide with autologous bone marrow reinfusion in patients with advanced cancer. J Clin Oncol.. 1987; 5: 260–265. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Eder J P, Elias A, Shea T C, et al, A phase I-II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumor patients. J Clin Oncol.. 1990; 7: 1239–1245
   Web of Science ®Google Scholar
• Peters W P, Eder J P, Henner W D, et al, High-dose combination alkylating agents with autologous bone marrow support: a phase I trial. J Clin Oncol.. 1986; 5: 646–654
   Google Scholar
• Slease R B, Benear G B, Selby G B, et al, High-dose combination alkylating agent therapy with autologous bone marrow rescue for refractory solid tumors. J Clin Oncol.. 1988; 6: 1314–1320. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Wheeler C, Antin J H, Hallowell C, et al, Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodkgin's disease and non-Hodgkin's lymphoma: a dose finding study. J Clin Oncol.. 1990; 8: 648–656. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Lilley E R, Rosenberg M C, Elion G B, et al, Synergistic interactions between cyclophosphamide or melphalan and VP-16 in a human rhabdomyosarcoma xenograft. Cancer Res.. 1990; 50: 284–287. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Herzig G P, Brown R, et al, Phase I-II studies of high-dose thiotepa and autologous BMT in patients with refractory malignancies. J Cell Biochem Suppl.. 1998, 12 Part C: 119
   Google Scholar
• Mason W P, Grovas A, Halpern S, et al, Intensive chemotherapy and bone marrow rescue for young children with newly diagnosed malignant brain tumors. J Clin Oncol.. 1998; 16: 210–221. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Papadopoulos K P, Garvin J H, Fetell M, et al, High-dose thiotepa and etoposide-based regimens with autologous hematopoietic support for high-risk or recurrent CNS tumors in children and adults. Bone Marrow Transplant. 1998; 22: 661–667. [CROSSREF], [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Kushner B H, Cheung N K, Kramer K, et al, Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults. Bone Marrow Transplant. 2001; 28: 551–556. [CROSSREF], [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Strother D, Ashley D, Kellie S J, et al, Feasibility of four consecutive high-dose chemotherapy cycles with stem-cell rescue for patients with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor after craniospinal radiotherapy: results of a Collaborative Study. J Clin Oncol.. 2001; 19: 2696–2704. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar